Jim joined Inverness Graham as part of the Value Creation Group in 2023. His responsibilities include serving on Inverness Graham portfolio company boards and as an advisor to various portfolio company CEOs and management teams, as well as supporting due diligence of investment opportunities in specific markets aligned with his background and experience.
Jim brings over 35 years of progressive executive experience in the highly regulated pharmaceutical, health & wellness, and consumer products sectors. As a seasoned leader, he has successfully guided four companies as President and CEO, enabling stakeholders and investment partners to achieve favorable outcomes.
Most recently, he transformed 22nd Century Group from a plant-based R&D biotechnology asset into a publicly traded, vertically integrated contract development and manufacturing organization (CDMO), serving the health and wellness consumer market. Jim’s transaction experience includes leading the private equity carve-out of Noramco from Johnson & Johnson/Janssen Pharmaceuticals and orchestrating the successful multi-billion-dollar exit of International Specialty Products (ISP) to a strategic buyer.